Shares of Veradigm Inc. (NASDAQ:MDRX - Get Free Report) traded up 8.5% during trading on Friday . The company traded as high as $4.99 and last traded at $4.99. 1,739 shares changed hands during mid-day trading, a decline of 99% from the average session volume of 322,204 shares. The stock had previously closed at $4.60.
Wall Street Analyst Weigh In
Separately, Wall Street Zen assumed coverage on shares of Veradigm in a report on Tuesday, May 20th. They set a "hold" rating for the company.
Get Our Latest Stock Analysis on MDRX
Veradigm Trading Up 9.8%
The business's fifty day moving average price is $4.43 and its 200-day moving average price is $5.44.
Veradigm Company Profile
(
Get Free Report)
Veradigm Inc, a healthcare technology company, provides information technology solutions and services to healthcare organizations in the United States, Canada, and internationally. It offers electronic health records (EHR), information connectivity, private cloud hosting, outsourcing, analytics, patient access, and population health management solutions.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Veradigm, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Veradigm wasn't on the list.
While Veradigm currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
